IL137566A0 - N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors - Google Patents
N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitorsInfo
- Publication number
- IL137566A0 IL137566A0 IL13756698A IL13756698A IL137566A0 IL 137566 A0 IL137566 A0 IL 137566A0 IL 13756698 A IL13756698 A IL 13756698A IL 13756698 A IL13756698 A IL 13756698A IL 137566 A0 IL137566 A0 IL 137566A0
- Authority
- IL
- Israel
- Prior art keywords
- aryl
- alkyl
- heteroarylamides
- sulfinyl
- sulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2637298A | 1998-02-19 | 1998-02-19 | |
PCT/US1998/017633 WO1999042436A1 (en) | 1998-02-19 | 1998-08-26 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IL137566A0 true IL137566A0 (en) | 2001-07-24 |
Family
ID=21831431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13756698A IL137566A0 (en) | 1998-02-19 | 1998-08-26 | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1054858A1 (en) |
JP (1) | JP2002503717A (en) |
KR (1) | KR20010041089A (en) |
CN (1) | CN1213021C (en) |
AU (1) | AU757719B2 (en) |
BG (1) | BG104782A (en) |
BR (1) | BR9815781A (en) |
CA (1) | CA2320469A1 (en) |
EA (1) | EA003283B1 (en) |
EE (1) | EE200000471A (en) |
GE (1) | GEP20022797B (en) |
HR (1) | HRP20000543A2 (en) |
HU (1) | HUP0101837A3 (en) |
ID (1) | ID25639A (en) |
IL (1) | IL137566A0 (en) |
NO (1) | NO20004093L (en) |
NZ (1) | NZ506184A (en) |
PL (1) | PL342548A1 (en) |
SK (1) | SK12332000A3 (en) |
TR (1) | TR200002423T2 (en) |
WO (1) | WO1999042436A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025687A1 (en) | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US20010039287A1 (en) * | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
BR0007784A (en) * | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Compound, method for inhibiting pathological changes mediated by the enzyme that converts tnf-alpha (tace) into a mammal, pharmaceutical composition, and, process for preparing a compound |
AR035312A1 (en) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
SK11352001A3 (en) | 1999-02-08 | 2002-09-10 | G. D. Searle & Co. | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
EP1252143A1 (en) * | 2000-01-27 | 2002-10-30 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
UY26664A1 (en) * | 2000-04-14 | 2001-11-30 | Abbott Lab | HYDRAZIDES AND ALCOXIAMIDAS INHIBITORS OF ANGIOGENESIS. |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
BR0209525A (en) | 2001-05-11 | 2004-03-09 | Pharmacia Corp | Aromatic sulfone hydroxamates and their use as protease inhibitors |
US7119203B2 (en) | 2002-04-25 | 2006-10-10 | Pharmacia Corporation | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
BR0312036A (en) * | 2002-06-25 | 2005-04-05 | Pharmacia Corp | arylsulfonyl hydroxamic acid and amide derivatives as well as pharmaceutical composition containing them and use thereof |
TW200418825A (en) | 2002-12-16 | 2004-10-01 | Hoffmann La Roche | Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives |
EP1812451A4 (en) * | 2004-11-01 | 2009-10-21 | Nuada Llc | Compounds and methods of use thereof |
FR2917427B1 (en) * | 2007-06-18 | 2009-08-21 | Galderma Res & Dev | TACE INHIBITORS IN ACNE TREATMENT |
FR2947268B1 (en) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS |
AU2013292076B2 (en) * | 2012-07-18 | 2017-02-23 | Proyecto De Biomedicina Cima, S.L. | New antifibrinolytic compounds |
KR101641023B1 (en) * | 2014-08-27 | 2016-07-20 | 씨제이헬스케어 주식회사 | Novel amino-phenyl-sulfonyl-acetate derivatives and use thereof |
WO2016032120A1 (en) * | 2014-08-27 | 2016-03-03 | 씨제이헬스케어 주식회사 | Novel amino-phenyl-sulfonyl-acetate derivative and use thereof |
CN107188837B (en) * | 2017-06-06 | 2019-05-28 | 温州大学 | A kind of synthetic method of α-acyl group high allyl thio-ether type compounds |
CN113194954A (en) | 2018-10-04 | 2021-07-30 | 国家医疗保健研究所 | EGFR inhibitors for the treatment of keratoderma |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
CA2181709A1 (en) * | 1994-01-22 | 1995-07-27 | Raymond Paul Beckett | Hydroxamic acid derivatives as metalloproteinase inhibitors |
AU690703B2 (en) * | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
GEP20022626B (en) * | 1997-02-27 | 2002-02-25 | American Cyanamid Company Us | N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors |
JPH11199512A (en) * | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | Use of mmp-13 selective inhibitor for the treatment of arthrosis deformans and other mmp-mediated disease |
WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
-
1998
- 1998-08-26 KR KR1020007009128A patent/KR20010041089A/en not_active Application Discontinuation
- 1998-08-26 PL PL98342548A patent/PL342548A1/en unknown
- 1998-08-26 EA EA200000849A patent/EA003283B1/en not_active IP Right Cessation
- 1998-08-26 ID IDW20001549A patent/ID25639A/en unknown
- 1998-08-26 EE EEP200000471A patent/EE200000471A/en unknown
- 1998-08-26 WO PCT/US1998/017633 patent/WO1999042436A1/en not_active Application Discontinuation
- 1998-08-26 HU HU0101837A patent/HUP0101837A3/en unknown
- 1998-08-26 IL IL13756698A patent/IL137566A0/en unknown
- 1998-08-26 SK SK1233-2000A patent/SK12332000A3/en unknown
- 1998-08-26 NZ NZ506184A patent/NZ506184A/en unknown
- 1998-08-26 JP JP2000532389A patent/JP2002503717A/en active Pending
- 1998-08-26 EP EP98943392A patent/EP1054858A1/en not_active Withdrawn
- 1998-08-26 CN CNB988139669A patent/CN1213021C/en not_active Expired - Fee Related
- 1998-08-26 TR TR2000/02423T patent/TR200002423T2/en unknown
- 1998-08-26 AU AU91201/98A patent/AU757719B2/en not_active Ceased
- 1998-08-26 BR BR9815781-7A patent/BR9815781A/en not_active Application Discontinuation
- 1998-08-26 GE GEAP19985554A patent/GEP20022797B/en unknown
- 1998-08-26 CA CA002320469A patent/CA2320469A1/en not_active Abandoned
-
2000
- 2000-08-16 NO NO20004093A patent/NO20004093L/en unknown
- 2000-08-18 HR HR20000543A patent/HRP20000543A2/en not_active Application Discontinuation
- 2000-09-19 BG BG104782A patent/BG104782A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20004093D0 (en) | 2000-08-16 |
CN1213021C (en) | 2005-08-03 |
GEP20022797B (en) | 2002-09-25 |
WO1999042436A1 (en) | 1999-08-26 |
HRP20000543A2 (en) | 2001-08-31 |
CA2320469A1 (en) | 1999-08-26 |
KR20010041089A (en) | 2001-05-15 |
HUP0101837A3 (en) | 2001-11-28 |
HUP0101837A2 (en) | 2001-10-28 |
CN1291183A (en) | 2001-04-11 |
SK12332000A3 (en) | 2001-02-12 |
BR9815781A (en) | 2000-11-07 |
JP2002503717A (en) | 2002-02-05 |
PL342548A1 (en) | 2001-06-18 |
AU9120198A (en) | 1999-09-06 |
EE200000471A (en) | 2002-02-15 |
EA200000849A1 (en) | 2001-04-23 |
EP1054858A1 (en) | 2000-11-29 |
EA003283B1 (en) | 2003-04-24 |
NO20004093L (en) | 2000-10-03 |
TR200002423T2 (en) | 2001-01-22 |
AU757719B2 (en) | 2003-03-06 |
BG104782A (en) | 2001-08-31 |
ID25639A (en) | 2000-10-19 |
NZ506184A (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1024875A1 (en) | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | |
HUP0101837A3 (en) | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | |
DK1114032T3 (en) | 4-Amino-substituted-2-substituted-1,2,3,4-tetrahydroquinolines as CETB inhibitors | |
DK1114033T3 (en) | 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors | |
AU2001259589A1 (en) | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | |
EE200000720A (en) | Novel 3-aryl-2-hydroxypropanoic acid derivative (I) | |
DK2253620T3 (en) | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN-TYROSINKINASE INHIBITORS | |
DE60215848D1 (en) | 1,2,4-thiadiazole compounds as melanocortinreceptor modulators | |
NO20004159D0 (en) | 2-pyridylmethylamine derivatives for use as fungicides | |
GC0000248A (en) | Novel heterocyclic sulfonamides | |
NO20016319D0 (en) | VLA-4 inhibitor compounds | |
NO20022558D0 (en) | 4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor | |
AU2594799A (en) | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors | |
NO20013675L (en) | 2,3,4,5-tetrahydro-1H- [1,4) benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors | |
EE200200050A (en) | Benzenamine derivatives as anticoagulants | |
AU6059999A (en) | 2-substituted heterocyclic sulfonamides | |
DK0949245T3 (en) | Process for alkylation of hindered sulfonamides | |
SI0973512T1 (en) | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | |
ZA995455B (en) | N-hydroxy-2(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors. | |
DE69929992D1 (en) | SEGMENTED TIREFORM TOOL | |
FR2828230B1 (en) | HINGE, ESPECIALLY FOR PIVOTING PANEL | |
AUPQ419599A0 (en) | Sulphur removal from offgas | |
DE29817235U1 (en) | Sternum closure |